|Codexis Introduces Codex™ Biocatalyst Panels|
|Next-Generation R&D Productivity Technology Enables Early Stage Adoption of Custom Biocatalysts by Pharma Manufacturers; Launched at Informex USA 2007 This Week |
Redwood City, CA - February 12, 2007
Codexis, Inc., a private biotechnology company, today introduced the Codex™ Biocatalyst Panels, a next-generation research product enabling pharmaceutical manufacturers to harness the power of biocatalysts to increase R&D and manufacturing productivity while significantly reducing cost. The potential for developing new biocatalysts to accelerate production of active pharmaceutical ingredients and intermediates needed to produce new human therapeutics can be readily evaluated using these panels. This can lead to faster, earlier development of efficient, lower-cost and environmentally sound manufacturing processes, well in advance of Phase III clinical trials.
The Codex™ Panels will be shown for the first time this week at Informex USA 2007 in San Francisco (February 13-16, www.informex.com).
“This product launch represents a significant evolution in our product offerings to pharmaceutical companies. Use of the Codex Panels can cut biocatalyst development time from months to weeks, and gives researchers hands-on insight into the applicability of our MolecularBreeding™ technology. Resulting development processes based on Codexis custom biocatalysts can reduce cost of goods and capital expenditures over many years,” said Alan Shaw, Ph.D., Codexis President and Chief Executive Officer.
“Until now, Codexis technology has been used for drug candidates selectively brought to us by innovator pharmaceutical manufacturers. The new panel approach enables customers to apply Codexis technology broadly in-house to identify optimizable biocatalytic process solutions for multiple drug candidates across their pipelines. Implementing customized biocatalytic processes early in the product life cycle can have a profound effect on our customers’ R&D and manufacturing efficiency and their competitive position, through cost reduction and creation of new intellectual property. It represents a major growth opportunity for Codexis,” Dr. Shaw added.
Codexis now offers sets of diagnostic enzyme panels that partners can use internally to screen for reactivity in desired process reactions. These enzymes have been optimized for use in pharmaceutical manufacturing, and are provided in a convenient 96-well format to efficiently determine if a biocatalytic solution is available for a chemically-challenging process step. The panels are designed to quickly and broadly exploit Codexis’ proprietary technologies. Panel data is used by Codexis to quickly develop product-specific, customized biocatalysts and biocatalytic processes for pharmaceutical partners.
Codexis, Inc. is a leading developer of biocatalytic process technologies that can substantially reduce the cost of manufacturing across a broad range of industries. Codexis' proprietary directed evolution technologies enable novel solutions for efficient, cost-effective and environmentally friendly processes for pharmaceutical, energy and industrial chemical applications. In 2006, Codexis was recognized by the U.S. Environmental Protection Agency with a Presidential Green Chemistry Challenge Award for developing an environmentally friendly, low-cost alternative manufacturing process. Codexis began operations in 2002. Codexis is a registered trademark of Codexis, Inc. For more information, please visit www.codexis.com